These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20858622)

  • 41. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 42. Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation exists.
    Carter JD
    Ann Rheum Dis; 2006 Dec; 65(12):1680. PubMed ID: 17105866
    [No Abstract]   [Full Text] [Related]  

  • 43. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
    Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessing the safety of new arthritis drugs: are we there yet?
    Suissa S
    J Rheumatol; 2008 Dec; 35(12):2295-7. PubMed ID: 19040315
    [No Abstract]   [Full Text] [Related]  

  • 45. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor.
    Hall HA; Zimmermann B
    Arthritis Rheum; 2006 Dec; 55(6):982-4. PubMed ID: 17139649
    [No Abstract]   [Full Text] [Related]  

  • 46. Differential risk of herpes zoster infection with biologic agent use in rheumatoid arthritis: comment on the article by Yun et al.
    Ranganathan P
    Arthritis Care Res (Hoboken); 2015 Jul; 67(7):1041. PubMed ID: 25470792
    [No Abstract]   [Full Text] [Related]  

  • 47. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.
    Rajakulendran S; Gadsby K; Allen D; O'Reilly S; Deighton C
    Ann Rheum Dis; 2006 Dec; 65(12):1678-9. PubMed ID: 17105865
    [No Abstract]   [Full Text] [Related]  

  • 48. [Rheumatology. TNF alpha-inhibitors: infection risks? Practical recommendations].
    Faucherre M; Pazar B; So A; Aubry-Rozier B
    Rev Med Suisse; 2011 Jan; 7(277):75-6, 78-9. PubMed ID: 21309182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vaccinations for rheumatoid arthritis.
    Perry LM; Winthrop KL; Curtis JR
    Curr Rheumatol Rep; 2014 Aug; 16(8):431. PubMed ID: 24925587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.
    Adelzadeh L; Jourabchi N; Wu JJ
    J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):846-52. PubMed ID: 25081573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis.
    Che H; Lukas C; Morel J; Combe B
    Joint Bone Spine; 2014 May; 81(3):215-21. PubMed ID: 23932722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reply: To PMID 25201241.
    Yun H; Badley JW; Curtis JR; Winthrop K
    Arthritis Care Res (Hoboken); 2015 Jul; 67(7):1041-2. PubMed ID: 25470750
    [No Abstract]   [Full Text] [Related]  

  • 53. Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Bruce ES; Kearsley-Fleet L; Watson KD; Symmons DP; Hyrich KL
    Rheumatology (Oxford); 2016 Jul; 55(7):1336-7. PubMed ID: 27118877
    [No Abstract]   [Full Text] [Related]  

  • 54. Improvement in Herpes Zoster Vaccination in Patients with Rheumatoid Arthritis: A Quality Improvement Project.
    Sheth H; Moreland L; Peterson H; Aggarwal R
    J Rheumatol; 2017 Jan; 44(1):11-17. PubMed ID: 28042124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab.
    Bassetti M; Pizzorni C; Gradoni L; Del Bono V; Cutolo M; Viscoli C
    Rheumatology (Oxford); 2006 Nov; 45(11):1446-8. PubMed ID: 16887847
    [No Abstract]   [Full Text] [Related]  

  • 56. Tumor necrosis factor blockade and the risk of viral infection.
    Kim SY; Solomon DH
    Nat Rev Rheumatol; 2010 Mar; 6(3):165-74. PubMed ID: 20142812
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention.
    Winthrop KL
    Rheum Dis Clin North Am; 2012 Nov; 38(4):727-45. PubMed ID: 23137579
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-tumor necrosis factor therapy in rheumatoid arthritis patients with a history of deep prosthetic joint infection: a report of four cases.
    Hirano Y; Kojima T; Kanayama Y; Shioura T; Hayashi M; Tsuboi S; Ishiguro N
    Mod Rheumatol; 2011 Oct; 21(5):542-7. PubMed ID: 21373797
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A 74-year-old female with recurrent infections receiving methotrexate for rheumatoid arthritis.
    Wijetilleka S; Chander S; Karim MY
    Rheumatology (Oxford); 2019 Jul; 58(7):1309-1310. PubMed ID: 30879043
    [No Abstract]   [Full Text] [Related]  

  • 60. [A rare complication in a patient with rheumatoid arthritis: sudden appearance of nodules on the forearm].
    Stiefelhagen P
    MMW Fortschr Med; 2012 Feb; 154(2):24. PubMed ID: 22352243
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.